BioNxt advances semaglutide oral dissolvable film program into active pharmaceutical development

• BioNxt Solutions Inc. moved its semaglutide oral dissolvable film program into active pharmaceutical development with German partner Gen-Plus GmbH.
• The sublingual thin-film formulation targets needle-free delivery for GLP-1 therapies used in obesity, metabolic disorders, and type 2 diabetes.
• The initial development phase is expected to run about six to nine months, focusing on formulation work, analytical methods, and early proof-of-concept evaluation.
• Proof-of-concept studies are slated to start once semaglutide API materials are received later this year, with positive results potentially supporting optimization, scale-up, and IP work.
• The update follows preclinical pharmacokinetic and tolerability results for BioNxt’s cladribine film program, which is advancing toward human bioequivalence studies in multiple sclerosis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNxt Solutions Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202605190305ACCESSWRNAPR_____1168157) on May 19, 2026, and is solely responsible for the information contained therein.